IDEAYA Biosciences is a promising biotech company targeting genetic vulnerabilities in cancer cells with synthetic lethality.

Topline results were announced from a phase 3 study assessing the immune response following coadministration of Arexvy and Shingrix.

If approved, the co-administration of Arexvy and Shingrix could provide a more convenient vaccination regimen for patients ...

In the study, co-administration of GSK's RSV vaccine Arexvy and shingles shot Shingrix elicited non-inferior immune responses ...

GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory ...

Research on human brain organoids is progressing at speed. Therefore, an ethical and legal framework needs to be put in place to ensure their responsible use, while not constraining innovation ...

British drugmaker GSK on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now ...

GSK Plc’s experimental mRNA flu vaccine showed a positive immune response against two key types of flu viruses in a mid-stage trial.

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza ... is a pioneering multinational biotech company founded in 2000 to advance the field of messenger RNA (mRNA) technology ...

The Life Sciences Generative AI Council aims to bring together the best minds in pharma, academia, and technology to advance the use of GenAI in life sciences R&D, seeking through pinpo The launch ...

GSK anticipates regulatory submission for Europe and Canada in 2025, as per a previous earnings report. Image credit: Shutterstock / OleksSH. GSK’s asthma drug Nucala (mepolizumab) has met the primary ...

Global healthcare company GlaxoSmithKline Pharmaceuticals Ltd on Tuesday (September 3) said it has received an income tax refund of ₹222.23 crore for the assessment year 2022-23, following an order ...